Statistiche di base
| CIK | 1407038 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BG Medicine, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| June 23, 2016 |
DEF 14A 1 d381148ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Com |
|
| May 5, 2016 |
15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-33827 BG MEDICINE, INC. (Exact name of registrant as specified i |
|
| April 29, 2016 |
Form 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 4, 2016 |
FOURTH AMENDMENT TO GALECTIN-3 LICENSE AND DISTRIBUTION AGREEMENT EX-10.7.4 Exhibit 10.7.4 FOURTH AMENDMENT TO GALECTIN-3 LICENSE AND DISTRIBUTION AGREEMENT THIS FOURTH AMENDMENT TO GALECTIN-3 LICENSE AND DISTRIBUTION AGREEMENT (this “Fourth Amendment”) is entered into as of November 24, 2015 and effective as of November 1, 2015 (the “Fourth Amendment Effective Date”) by and between Abbott Laboratories, a corporation of the state of Illinois, having its principa |
|
| April 4, 2016 |
10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33827 BG MEDICI |
|
| March 31, 2016 |
NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: December 31, 2015 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition |
|
| March 31, 2016 |
Results of Operations and Financial Condition, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 25, 2016 BG Medicine, Inc. |
|
| March 29, 2016 |
S-8 POS As filed with the Securities and Exchange Commission on March 29, 2016 Registration No. |
|
| March 29, 2016 |
S-8 POS As filed with the Securities and Exchange Commission on March 29, 2016 Registration No. |
|
| March 29, 2016 |
S-8 POS As filed with the Securities and Exchange Commission on March 29, 2016 Registration No. |
|
| March 29, 2016 |
S-8 POS As filed with the Securities and Exchange Commission on March 29, 2016 Registration No. |
|
| March 29, 2016 |
S-8 POS As filed with the Securities and Exchange Commission on March 29, 2016 Registration No. |
|
| March 29, 2016 |
S-8 POS As filed with the Securities and Exchange Commission on March 29, 2016 Registration No. |
|
| March 29, 2016 |
S-8 POS As filed with the Securities and Exchange Commission on March 29, 2016 Registration No. |
|
| March 29, 2016 |
POS AM As filed with the Securities and Exchange Commission on March 29, 2016 Registration No. |
|
| February 4, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 4, 2016 BG Medicine, Inc. |
|
| January 19, 2016 |
BGMD / BG Medicine, Inc. / Empery Asset Management, LP - BG MEDICINE, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* BG Medicine, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 08861T206 (CUSIP Number) December 31, 2015 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| December 23, 2015 |
EX-99.1 2 d25204dex991.htm EX-99.1 Exhibit 99.1 BG Medicine Withdraws 510(k) Premarket Notification for Proposed Additional Indication for the BGM Galectin-3® Test Waltham, MA, December 23, 2015 – BG Medicine, Inc. (OTC QB:BGMD) today announced that it has submitted to the FDA a notice of withdrawal of its 510(k) premarket notification filing with the US Food and Drug Administration (“FDA”) that w |
|
| December 23, 2015 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 18, 2015 BG Medicine, Inc. |
|
| December 4, 2015 |
EX-16.1 Exhibit 16.1 December 4, 2015 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549-7561 Dear Sirs/Madams: We have read Item 4.01(a) of BG Medicine, Inc.?s Form 8-K dated December 4, 2015, and we agree with the statements made therein. Yours truly, /s/ DELOITTE & TOUCHE LLP Boston, Massachusetts |
|
| December 4, 2015 |
BG Medicine FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 3, 2015 BG Medicine, Inc. |
|
| November 30, 2015 |
EX-99.1 Exhibit 99.1 License and Distribution Agreement Amended Adoption of Automated Testing for Galectin-3 by Reference Laboratories Expected to Expand Waltham, Mass., November 30, 2015 ? BG Medicine, Inc. (OTCQB: BGMD), the developer of the BGM Galectin-3? Test, today announced an amendment to its license and distribution agreement for Galectin-3. Amendment to License and Distribution Agreement |
|
| November 30, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 24, 2015 BG Medicine, Inc. |
|
| November 23, 2015 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 23, 2015 BG Medicine, Inc. |
|
| November 20, 2015 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 17, 2015 BG Medicine, Inc. |
|
| November 20, 2015 |
BG MEDICINE, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY EX-10.1 2 d50107dex101.htm EX-10.1 Exhibit 10.1 Effective: November 18, 2015 BG MEDICINE, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The Board of Directors of BG Medicine, Inc. (the “Company”) has approved the following Non-Employee Director Compensation Policy (this “Policy”) which establishes compensation to be paid to non-employee directors of the Company, effective as |
|
| November 17, 2015 |
BG Medicine Reports Third Quarter 2015 Financial Results EX-99.1 2 d10803dex991.htm EX-99.1 Exhibit 99.1 BG Medicine Reports Third Quarter 2015 Financial Results Waltham, Mass., November 17, 2015 – BG Medicine, Inc. (OTCQB: BGMD), the developer of the BGM Galectin-3® Test, today reported financial results for the three and nine months ended September 30, 2015. “Our operating results in the third quarter of 2015 reflect our ongoing efforts to extend our |
|
| November 17, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 17, 2015 BG Medicine, Inc. |
|
| September 25, 2015 |
BG Medicine FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 21, 2015 BG Medicine, Inc. |
|
| September 15, 2015 |
BG MEDICINE TO BEGIN TRADING ON THE OTCQB EX-99.1 2 d50600dex991.htm EX-99.1 Exhibit 99.1 BG MEDICINE TO BEGIN TRADING ON THE OTCQB WALTHAM, Mass., Sept. 15, 2015 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3(R) Test, today announced that on September 14, 2015, the Company was notified by The NASDAQ Stock Market LLC (“NASDAQ”) that trading in the Company’s common stock will be suspended on NASDAQ |
|
| September 15, 2015 |
BG Medicine FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 14, 2015 BG Medicine, Inc. |
|
| August 21, 2015 |
BGMD / BG Medicine, Inc. / Empery Asset Management, LP - BG MEDICINE, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* BG Medicine, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 08861T206 (CUSIP Number) August 13, 2015 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this Sche |
|
| August 18, 2015 |
AMENDED AND RESTATED CERTIFICATE OF DESIGNATIONS SERIES A PREFERRED STOCK BG MEDICINE, INC. EX-3.1 Exhibit 3.1 Filing Copy AMENDED AND RESTATED CERTIFICATE OF DESIGNATIONS OF SERIES A PREFERRED STOCK OF BG MEDICINE, INC. BG Medicine, Inc., a Delaware corporation (the ?Company?), does hereby certify, pursuant to authority conferred on the Board of Directors of the Company (the ?Board?) by the Restated Certificate of Incorporation of the Company (the ?Certificate of Incorporation?), and pu |
|
| August 18, 2015 |
EX-1.1 2 d21473dex11.htm EX-1.1 Exhibit 1.1 2,315,654 Shares of Common Stock par value $0.001 Pre-Funded Warrants exercisable into 184,346 Shares of Common Stock Warrants to purchase 1,250,000 Shares of Common Stock BG MEDICINE, INC. UNDERWRITING AGREEMENT August 13, 2015 ROTH CAPITAL PARTNERS, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Dear Sirs: 1. INTRODUCTION. BG Medicine, I |
|
| August 18, 2015 |
EX-4.1 4 d21473dex41.htm EX-4.1 Exhibit 4.1 PREFUNDED COMMON STOCK PURCHASE WARRANT BG MEDICINE, INC. Warrant Shares: Initial Exercise Date: , 2015 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time |
|
| August 18, 2015 |
COMMON STOCK PURCHASE WARRANT BG MEDICINE, INC. Warrant Shares: Initial Exercise Date: , 2015 EX-4.2 Exhibit 4.2 COMMON STOCK PURCHASE WARRANT BG MEDICINE, INC. Warrant Shares: Initial Exercise Date: , 2015 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after (the ?Initial Exercise Date?) and |
|
| August 18, 2015 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 13, 2015 BG Medicine, Inc. |
|
| August 18, 2015 |
8-K 1 d21473d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 12, 2015 BG Medicine, Inc. (Exact Name of Registrant as Specified in Its Charter) 001-33827 (Commission File Number) Delaware 04-3506204 (State or Ot |
|
| August 18, 2015 |
BG Medicine Prices Underwritten Public Offering EX-99.2 Exhibit 99.2 BG Medicine Prices Underwritten Public Offering WALTHAM, Mass. ? August 13, 2015 ? (NASDAQ: BGMD) BG Medicine, Inc., the developer of the BGM Galectin-3? Test, today announced the pricing of an underwritten public offering of its equity securities. Roth Capital Partners is acting as sole manager for the offering. The company is offering 2,315,654 Series A units, each consistin |
|
| August 18, 2015 |
BG Medicine Announces Proposed Underwritten Public Offering EX-99.1 Exhibit 99.1 BG Medicine Announces Proposed Underwritten Public Offering WALTHAM, Mass. ? August 12, 2015 ? (NASDAQ: BGMD), BG Medicine, Inc., the developer of the BGM Galectin-3? Test, today announced that it intends to offer and sell equity securities in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or |
|
| August 14, 2015 |
Prospectus Supplement Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. |
|
| August 14, 2015 |
EX-99.1 2 d66655dex991.htm EX-99.1 Exhibit 99.1 BG Medicine Provides Business Update and Reports Second Quarter 2015 Financial Results Focus Shifts to Support of Market Introduction of Automated Galectin-3 Test in U.S. Operating Cash Burn for Second Quarter of 2015 Reduced by 68% from Second Quarter of 2014 —Company to Host Business Update Conference Call on Wednesday, August 19, 2015— Waltham, Ma |
|
| August 14, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 14, 2015 BG Medicine, Inc. |
|
| August 12, 2015 |
SUBJECT TO COMPLETION, DATED AUGUST 12, 2015 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-204307 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell nor do they seek an offer to buy these securities in any jurisdiction where the offer or sale |
|
| August 3, 2015 |
BGMD / BG Medicine, Inc. / AGTC ADVISORS FUND LP - AMENDMENT 4 TO SCHEDULE 13D Activist Investment Amendment 4 to Schedule 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* BG Medicine, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 08861T107 (CUSIP Number) Charles Carelli Chief Financial Officer Flagship Ventures One Memorial Drive, 7th Floor Cambridge, MA 02142 |
|
| July 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 14, 2015 BG Medicine, Inc. |
|
| July 15, 2015 |
CERTIFICATE OF DESIGNATIONS SERIES A PREFERRED STOCK BG MEDICINE, INC. EX-3.1 Exhibit 3.1 CERTIFICATE OF DESIGNATIONS OF SERIES A PREFERRED STOCK OF BG MEDICINE, INC. The undersigned, Paul R. Sohmer, M.D., the President and Chief Executive Officer of BG Medicine, Inc. (including any successor in interest, the ?Company?), a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify, in accordance wit |
|
| July 15, 2015 |
BG MEDICINE, INC. FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT July 14, 2015 EX-10.1 Exhibit 10.1 BG MEDICINE, INC. FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT July 14, 2015 Reference is hereby made to that certain Securities Purchase Agreement (the ?Purchase Agreement?), dated as of May 12, 2015, by and among BG Medicine, Inc. (the ?Company?) and the purchasers named therein (the ?Purchasers?). Capitalized terms used and not defined herein shall have the meanings giv |
|
| July 15, 2015 |
BG MEDICINE, INC. FIFTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT EX-10.2 Exhibit 10.2 Execution Version BG MEDICINE, INC. FIFTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT THIS FIFTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the ?Agreement?) is made as of July 14, 2015, by and among BG Medicine, Inc., a Delaware corporation (the ?Company?), and the holders of capital stock of the Company as set forth on Schedule A hereto (the ?Stockholders?). R E C I T |
|
| July 15, 2015 |
BG Medicine Announces Payoff of Secured Term Loan EX-99.1 Exhibit 99.1 BG Medicine Announces Payoff of Secured Term Loan WALTHAM, Mass., July 15, 2015 (GLOBE NEWSWIRE) ? BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3? Test, announced today that it has paid off its secured term loan facility with General Electric Capital Corporation and Comerica Bank. The secured term loan in the aggregate principal amount of $10 million was |
|
| July 8, 2015 |
CERTIFICATE OF AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION OF BG MEDICINE, INC. EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION OF BG MEDICINE, INC. It is hereby certified that: FIRST: The name of the corporation is BG Medicine, Inc. (the ?Corporation?). SECOND: The Restated Certificate of Incorporation of the Corporation, as amended to date, is hereby further amended by striking out Section A of Article Fourth in its entirety and by subst |
|
| July 8, 2015 |
EX-99.1 Exhibit 99.1 BG Medicine Announces One-for-Four Reverse Stock Split Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on July 9, 2015 WALTHAM, Mass., July 8, 2015 (GLOBE NEWSWIRE) ? BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3? Test, today announced the effectiveness of a one-for-four reverse stock split of its common stock. The reverse stock split |
|
| July 8, 2015 |
BG Medicine FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 8, 2015 BG Medicine, Inc. |
|
| July 7, 2015 |
Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 7, 2015 BG Medicine, Inc. |
|
| July 6, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 2, 2015 BG Medicine, Inc. |
|
| July 6, 2015 |
First Automated Test for Galectin-3 Now Available in U.S. EX-99.1 Exhibit 99.1 First Automated Test for Galectin-3 Now Available in U.S. WALTHAM, Mass., July 6, 2015 (GLOBE NEWSWIRE) ? BG Medicine, Inc. (Nasdaq: BGMD), the developer of the BGM Galectin-3? Test, today announced that the ARCHITECT? Galectin-3 assay is now available. This automated blood test was cleared by the United States Food and Drug Administration (FDA) for use in conjunction with cli |
|
| July 6, 2015 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 6, 2015 BG Medicine, Inc. |
|
| June 9, 2015 |
EX-10.1 EXECUTION VERSION EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of May 12, 2015, by and among BG Medicine, Inc., Delaware corporation (the ?Company?), and the parties set forth on Annex A hereto as Purchasers (each a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, the Company has authorized the issuance and sale pursuan |
|
| June 9, 2015 |
BG MEDICINE, INC. SECURITY AGREEMENT EX-10.2 Exhibit 10.2 Execution Version THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS EVIDENCED HEREBY AND ANY LIENS OR OTHER SECURITY INTERESTS SECURING SUCH RIGHTS AND OBLIGATIONS ARE SUBORDINATE IN THE MANNER AND TO THE EXTENT SET FORTH IN THAT CERTAIN SUBORDINATION AND INTERCREDITOR AGREEMENT (AS AMENDED, RESTATED, SUPPLEMENTED OR MODIFIED FROM TIME TO TIME, THE ?SUBORDINATION AGREEMENT?) DATED |
|
| June 9, 2015 |
SUBORDINATION AND INTERCREDITOR AGREEMENT EX-10.3 Exhibit 10.3 Execution Version SUBORDINATION AND INTERCREDITOR AGREEMENT THIS SUBORDINATION AND INTERCREDITOR AGREEMENT (this ?Agreement?) is entered into as of May 12, 2015, by and among the holders of the Subordinated Debt (as defined below) signatory hereto from time to time and their permitted successors and assigns (collectively, the ?Subordinated Creditor?), and GENERAL ELECTRIC CAPI |
|
| June 9, 2015 |
BG Medicine 8-K/A (Current Report/Significant Event) 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Amendment No. |
|
| June 9, 2015 |
BG MEDICINE, INC. FORM OF SECURED CONVERTIBLE PROMISSORY NOTE May 12, 2015 $ [ ] EX-4.1 Exhibit 4.1 THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), AND ARE ?RESTRICTED SECURITIES? AS DEFINED IN RULE 144 PROMULGATED UNDER THE ACT. THEY MAY NOT BE SOLD OR OFFERED FOR SALE OR OTHERWISE DISTRIBUTED EXCEPT (I) IN CONJUNCTION WITH AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES |
|
| June 9, 2015 |
CERTIFICATE OF DESIGNATIONS SERIES A PREFERRED STOCK BG MEDICINE, INC. EX-3.1 Exhibit 3.1 FILING COPY CERTIFICATE OF DESIGNATIONS OF SERIES A PREFERRED STOCK OF BG MEDICINE, INC. The undersigned, Paul R. Sohmer, M.D., the President and Chief Executive Officer of BG Medicine, Inc. (including any successor in interest, the ?Company?), a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify, in ac |
|
| June 9, 2015 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| June 9, 2015 |
BG MEDICINE, INC. FIFTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT EX-10.5 Exhibit 10.5 Execution Version BG MEDICINE, INC. FIFTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT THIS FIFTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the ?Agreement?) is made as of [ ], 2015, by and among BG Medicine, Inc., a Delaware corporation (the ?Company?), and the holders of capital stock of the Company as set forth on Schedule A hereto (the ?Stockholders?). R E C I T A L |
|
| June 9, 2015 |
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT EX-10.4 Exhibit 10.4 Execution Version SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?) is entered into as of May 12, 2015, by and among BG MEDICINE, INC., a Delaware corporation (?Borrower?); GENERAL ELECTRIC CAPITAL CORPORATION, a Delaware corporation (in its individual capacity, ?GE Capital?), for itself as Lender and as Age |
|
| June 5, 2015 |
BG MEDICINE, INC. COMMON STOCK PREFERRED STOCK DEBT SECURITIES PURCHASE CONTRACTS Prospectus Table of Contents Filed Pursuant to Rule 424(b)(2) Registration Statement 333-204307 PROSPECTUS BG MEDICINE, INC. |
|
| June 3, 2015 |
Acceleration Request BG MEDICINE, INC. 880 Winter Street, Suite 210 Waltham, Massachusetts 02451 June 3, 2015 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler, Assistant Director RE: BG Medicine, Inc. Registration Statement on Form S-3 Filed May 19, 2015 File No. 333-204307 Acceleratio |
|
| May 26, 2015 |
SCHEDULE 13D CUSIP No. 08861T107 Page 20 of 21 EX-1 SCHEDULE 13D CUSIP No. 08861T107 Page 20 of 21 Exhibit 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing addi |
|
| May 26, 2015 |
BGMD / BG Medicine, Inc. / AGTC ADVISORS FUND LP - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* BG Medicine, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 08861T107 (CUSIP Number) Charles Carelli Chief Financial Officer Flagship Ventures One Memorial Drive, 7th Floor Cambridge, MA 02142 617-868-1888 (Name, |
|
| May 19, 2015 |
Exhibit 4.8 BG MEDICINE, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). 5.04(a) |
|
| May 19, 2015 |
Table of Contents As filed with the Securities and Exchange Commission on May 19, 2015 Registration No. |
|
| May 19, 2015 |
EX-4.9 Exhibit 4.9 BG MEDICINE, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 31 |
|
| May 19, 2015 |
FORM S-8 As filed with the Securities and Exchange Commission on May 19, 2015 Registration No. |
|
| May 14, 2015 |
BG Medicine FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 14, 2015 BG Medicine, Inc. |
|
| May 14, 2015 |
EX-99.1 Exhibit 99.1 BG Medicine Reports First Quarter 2015 Financial Results Net Loss Reduced by 38% and Operating Cash Burn Cut by 42% from First Quarter 2014 Outlook Improved for 2015 WALTHAM, Mass., May 14, 2015 (GLOBE NEWSWIRE) ? BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3? Test, today reported financial results for the first quarter of 2015. ?We continue to prepare f |
|
| May 12, 2015 |
BG MEDICINE, INC. SECURITY AGREEMENT EX-10.2 Exhibit 10.2 Execution Version THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS EVIDENCED HEREBY AND ANY LIENS OR OTHER SECURITY INTERESTS SECURING SUCH RIGHTS AND OBLIGATIONS ARE SUBORDINATE IN THE MANNER AND TO THE EXTENT SET FORTH IN THAT CERTAIN SUBORDINATION AND INTERCREDITOR AGREEMENT (AS AMENDED, RESTATED, SUPPLEMENTED OR MODIFIED FROM TIME TO TIME, THE ?SUBORDINATION AGREEMENT?) DATED |
|
| May 12, 2015 |
EX-10.1 4 d923806dex101.htm EX-10.1 EXECUTION VERSION EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of May 12, 2015, by and among BG Medicine, Inc., Delaware corporation (the “Company”), and the parties set forth on Annex A hereto as Purchasers (each a “Purchaser” and collectively, the “Purchasers”). WHEREAS, the Company has authorized t |
|
| May 12, 2015 |
BG Medicine 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 8, 2015 BG Medicine, Inc. |
|
| May 12, 2015 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 12, 2015 |
CERTIFICATE OF DESIGNATIONS SERIES A PREFERRED STOCK BG MEDICINE, INC. Exhibit 3.1 FILING COPY CERTIFICATE OF DESIGNATIONS OF SERIES A PREFERRED STOCK OF BG MEDICINE, INC. The undersigned, Paul R. Sohmer, M.D., the President and Chief Executive Officer of BG Medicine, Inc. (including any successor in interest, the Company), a corporation organized and existing under the General Corporation Law of the State of Delaware (the DGCL), does hereby certify, in accordanc |
|
| May 12, 2015 |
BG MEDICINE, INC. FIFTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT EX-10.5 Exhibit 10.5 Execution Version BG MEDICINE, INC. FIFTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT THIS FIFTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the ?Agreement?) is made as of [ ], 2015, by and among BG Medicine, Inc., a Delaware corporation (the ?Company?), and the holders of capital stock of the Company as set forth on Schedule A hereto (the ?Stockholders?). R E C I T A L |
|
| May 12, 2015 |
SUBORDINATION AND INTERCREDITOR AGREEMENT EX-10.3 Exhibit 10.3 Execution Version SUBORDINATION AND INTERCREDITOR AGREEMENT THIS SUBORDINATION AND INTERCREDITOR AGREEMENT (this ?Agreement?) is entered into as of May 12, 2015, by and among the holders of the Subordinated Debt (as defined below) signatory hereto from time to time and their permitted successors and assigns (collectively, the ?Subordinated Creditor?), and GENERAL ELECTRIC CAPI |
|
| May 12, 2015 |
BG MEDICINE, INC. FORM OF SECURED CONVERTIBLE PROMISSORY NOTE May 12, 2015 $ [ ] EX-4.1 Exhibit 4.1 THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), AND ARE ?RESTRICTED SECURITIES? AS DEFINED IN RULE 144 PROMULGATED UNDER THE ACT. THEY MAY NOT BE SOLD OR OFFERED FOR SALE OR OTHERWISE DISTRIBUTED EXCEPT (I) IN CONJUNCTION WITH AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES |
|
| May 12, 2015 |
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT Exhibit 10.4 Execution Version SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this Amendment) is entered into as of May 12, 2015, by and among BG MEDICINE, INC., a Delaware corporation (Borrower); GENERAL ELECTRIC CAPITAL CORPORATION, a Delaware corporation (in its individual capacity, GE Capital), for itself as Lender and as Agent for L |
|
| April 15, 2015 |
BG Medicine 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 9, 2015 BG Medicine, Inc. |
|
| March 31, 2015 |
BG Medicine 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 31, 2015 BG Medicine, Inc. |
|
| March 31, 2015 |
EX-99.1 Exhibit 99.1 BG Medicine Reports 2014 Fourth Quarter and Year End Financial Results Net Loss Reduced by 49% and Operating Cash Burn Cut by 47% From 2013 First Automated Galectin-3 Testing Expected to Launch in U.S. in Mid-2015 Waltham, Mass., March 31, 2015 ? BG Medicine, Inc. (NASDAQ: BGMD), the developer of the BGM Galectin-3? Test, today reported financial results for the three months a |
|
| March 13, 2015 |
BG Medicine 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 10, 2015 BG Medicine, Inc. |
|
| February 17, 2015 |
BGMD / BG Medicine, Inc. / GE ASSET MANAGEMENT - BG MEDICINE, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.2)* BG Medicine, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 08861T107 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 13, 2015 |
BGMD / BG Medicine, Inc. / CAPITAL VENTURES INTERNATIONAL - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* BG Medicine, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 08861T107 (CUSIP Number) December 31, 2014 (Dat |
|
| December 30, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 29, 2014 BG Medicine, Inc. |
|
| December 24, 2014 |
BG MEDICINE, INC. 4,106,071 Shares of Common Stock Prospectus Supplement Table of Contents PROSPECTUS SUPPLEMENT NO. 1 (TO PROSPECTUS DATED JULY 16, 2014) Filed pursuant to Rule 424(b)(3) under the Securities Act of 1933 in connection with Registration Statement No. 333-188211 BG MEDICINE, INC. 4,106,071 Shares of Common Stock This Prospectus Supplement No. 1 supplements and amends the prospectus dated July 16, 2014 relating to the sale of up to 4 |
|
| December 19, 2014 |
BGMD / BG Medicine, Inc. / NEWCOGEN GROUP LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* BG Medicine, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 08861T107 (CUSIP Number) Charles Carelli Chief Financial Officer Flagship Ventures One Memorial Drive, 7th Floor Cambridge, MA 02142 617-868-1888 (Name, |
|
| November 26, 2014 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 20, 2014 BG Medicine, Inc. |
|
| November 13, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 13, 2014 BG Medicine, Inc. |
|
| November 13, 2014 |
EX-99.1 Exhibit 99.1 BG Medicine Reports Third Quarter 2014 Financial Results Net Loss Reduced by 35% and Operating Cash Burn Cut by 48% From Third Quarter 2013 Company Retains Investment Bank to Explore Strategic Alternatives WALTHAM, Mass., November 13, 2014 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today reported financial results for the thi |
|
| October 17, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 16, 2014 BG Medicine, Inc. |
|
| September 11, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 5, 2014 BG Medicine, Inc. |
|
| August 14, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 14, 2014 BG Medicine, Inc. |
|
| August 14, 2014 |
EX-99.1 Exhibit 99.1 BG Medicine Reports Second Quarter 2014 Financial Results Net Loss Reduced by 55% and Operating Cash Burn Cut by 43% From Second Quarter 2013 WALTHAM, Mass., August 14, 2014 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today reported financial results for the second quarter 2014. Second Quarter Results The Company reported net |
|
| July 16, 2014 |
BG MEDICINE, INC. 4,106,071 shares of Common Stock Prospectus Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-188211 PROSPECTUS BG MEDICINE, INC. 4,106,071 shares of Common Stock This prospectus covers the sale of an aggregate of 4,106,071 shares of our common stock, $0.001 par value per share, or the Common Stock, by Aspire Capital Fund, LLC, referred to herein as Aspire Capital or the Selling Stockholder. The prices at wh |
|
| July 7, 2014 |
BGMD / BG Medicine, Inc. S-8 - - FORM S-8 Form S-8 As filed with the Securities and Exchange Commission on July 7, 2014 Registration No. |
|
| July 7, 2014 |
BGMD / BG Medicine, Inc. POS AM - - POST-EFFECTIVE AMENDMENT NO.1 TO FORM S-1 Post-Effective Amendment No.1 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on July 7, 2014 Registration Statement No. 333-188211 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-effective Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 BG MEDICINE, INC. (Exact Name of Registrant as Specified in It |
|
| June 5, 2014 |
Submission of Matters to a Vote of Security Holders - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 3, 2014 BG Medicine, Inc. |
|
| May 14, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 14, 2014 BG Medicine, Inc. |
|
| May 14, 2014 |
EX-99.1 Exhibit 99.1 BG MEDICINE REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS Net Loss Reduced by 60% and Operating Cash Burn Cut by 44% from First Quarter 2013 Continued Progress Made Toward Delivering on Critical Catalysts for Growth Waltham, Mass., May 14, 2014 – BG Medicine, Inc. (NASDAQ: BGMD), the developer of the BGM Galectin-3® Test, today reported financial results for the first quarter e |
|
| April 24, 2014 |
DEFR14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 24, 2014 |
- DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 24, 2014 |
Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 11, 2014 |
BGMD / BG Medicine, Inc. / CAPITAL VENTURES INTERNATIONAL - SC 13G Passive Investment CUSIP No. 08861T107 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* BG Medicine, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 08861T107 (CUSIP Number) |
|
| April 3, 2014 |
BG MEDICINE, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK EX-99.1 Exhibit 99.1 BG MEDICINE, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK WALTHAM, Mass., April 2, 2014 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. BG Medicine also expects to grant the underwriters a 30-day option to pu |
|
| April 3, 2014 |
EX-1.1 Exhibit 1.1 EXECUTION VERSION 6,452,000 Shares of Common Stock par value $0.001 967,800 Over-Allotment Shares BG MEDICINE, INC. UNDERWRITING AGREEMENT April 3, 2014 LAZARD CAPITAL MARKETS LLC 30 Rockefeller Plaza New York, New York 10020 Dear Sirs: 1. INTRODUCTION. BG Medicine, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to Lazard Capital Markets LLC (the “Under |
|
| April 3, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 2, 2014 BG Medicine, Inc. |
|
| April 3, 2014 |
BG Medicine, Inc. Prices $10.0 Million Public Offering of Common Stock EX-99.2 Exhibit 99.2 BG Medicine, Inc. Prices $10.0 Million Public Offering of Common Stock Waltham, Mass., April 3, 2014 — BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today announced the pricing of the sale of 6,452,000 shares of its common stock in an underwritten public offering at a price to the public of $1.55 per share. The net offering proceeds to BG Medicine |
|
| April 3, 2014 |
6,452,000 Shares of Common Stock Prospectus Supplement Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. |
|
| April 2, 2014 |
SUBJECT TO COMPLETION, DATED APRIL 2, 2014 Prospectus Supplement Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. |
|
| March 27, 2014 |
BG Medicine FORM 10-K (Annual Report) Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 20, 2014 |
BG Medicine Reports 2013 Fourth Quarter and Year End Financial Results EX-99.1 Exhibit 99.1 BG Medicine Reports 2013 Fourth Quarter and Year End Financial Results Waltham, Mass., March 20, 2014 -GLOBENEWSWIRE- BG Medicine, Inc. (NASDAQ: BGMD), the developer of the BGM Galectin-3® Test, today reported financial results for the three months ended and year ended December 31, 2013. The Company reported total revenues for the full year of $ 4.1 million, a 45% increase fro |
|
| March 20, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 20, 2014 BG Medicine, Inc. |
|
| March 12, 2014 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 11, 2014 BG Medicine, Inc. |
|
| March 12, 2014 |
BG Medicine Compliant With NASDAQ Listing Requirements EX-99.1 Exhibit 99.1 BG Medicine Compliant With NASDAQ Listing Requirements WALTHAM, Mass., March 11, 2014 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD) (the “Company”) today announced that it has received correspondence from The NASDAQ Stock Market LLC (“NASDAQ”) confirming that the Company has evidenced compliance with the requirements for continued listing on The NASDAQ Capital Market. Acc |
|
| February 14, 2014 |
BGMD / BG Medicine, Inc. / CLEARBRIDGE, LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 03)* BG Medicine, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 08861T107 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| January 27, 2014 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 27, 2014 BG Medicine, Inc. |
|
| January 27, 2014 |
BG Medicine to transfer to the NASDAQ Capital Market; Obtains Requested NASDAQ extension EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE BG Medicine to transfer to the NASDAQ Capital Market; Obtains Requested NASDAQ extension WALTHAM, Mass., Jan. 27, 2014 (GLOBENEWSWIRE) BG Medicine, Inc. (BGMD) (the “Company”) announced today that the NASDAQ Listing Qualifications Panel (the “Panel”) has granted the Company’s request for the transfer of its listing from The NASDAQ Global Market to The NAS |
|
| December 18, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 17, 2013 BG Medicine, Inc. |
|
| December 10, 2013 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 10, 2013 BG Medicine, Inc. |
|
| December 10, 2013 |
BG Medicine Welcomes Final Determination by CMS of 2014 Reimbursement for BGM Galectin-3 EX-99.1 Exhibit 99.1 BG Medicine Welcomes Final Determination by CMS of 2014 Reimbursement for BGM Galectin-3® Test WALTHAM, Mass., Dec. 10, 2013 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq: BGMD) announced today that the Centers for Medicare and Medicaid Services (CMS) have published the final determination of the 2014 Medicare national limitation amount for the Company’s galectin-3 blood test ( |
|
| November 27, 2013 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 22, 2013 BG Medicine, Inc. |
|
| November 15, 2013 |
EX-99.1 Exhibit 99.1 November 14, 2013 BG Medicine, Inc. Appoints Stephen P. Hall as Chief Financial Officer WALTHAM, Mass., Nov. 14, 2013 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, announced today that its Board of Directors has appointed Stephen P. Hall, as the company’s Executive Vice President, Chief Financial Officer. Mr. Hall most recently |
|
| November 15, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 13, 2013 BG Medicine, Inc. |
|
| November 12, 2013 |
BG MEDICINE, INC. 4,106,071 Shares of Common Stock 424B3 Table of Contents PROSPECTUS SUPPLEMENT NO. 3 (TO PROSPECTUS DATED JUNE 7, 2013) Filed pursuant to Rule 424(b)(3) under the Securities Act of 1933 in connection with Registration Statement No. 333-188211 BG MEDICINE, INC. 4,106,071 Shares of Common Stock This Prospectus Supplement No. 3 supplements and amends the prospectus dated June 7, 2013 relating to the sale of up to 4,106,071 shares of |
|
| November 6, 2013 |
EX-99.1 Exhibit 99.1 BG Medicine Reports 2013 Third Quarter Financial Results Capital Health Accountable Care Organization LLC Adopts BGM Galectin-3® Test Network of Laboratories in U.S. Offering BGM Galectin-3 Test Expanded Full-Year 2013 Product Revenue and Cash Burn Guidance Confirmed Waltham, Mass., November 6, 2013 – BG Medicine, Inc. (NASDAQ: BGMD), the developer of the BGM Galectin-3 Test, |
|
| November 6, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 6, 2013 BG Medicine, Inc. |
|
| October 21, 2013 |
Amendment No.1 to Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* BG MEDICINE, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 08861T107 (CUSIP Number) October 1, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| September 27, 2013 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 23, 2013 BG Medicine, Inc. |
|
| August 15, 2013 |
BG MEDICINE, INC. 4,106,071 Shares of Common Stock Prospectus Supplement Table of Contents Filed pursuant to Rule 424(b)(3) under the Securities Act of 1933 in connection with Registration Statement No. |
|
| August 15, 2013 |
BG MEDICINE, INC. 4,106,071 Shares of Common Stock Prospectus Supplement Table of Contents Filed pursuant to Rule 424(b)(3) under the Securities Act of 1933 in connection with Registration Statement No. |
|
| August 8, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 8, 2013 BG Medicine, Inc. |
|
| August 8, 2013 |
EX-99.1 Exhibit 99.1 BG Medicine Reports 2013 Second Quarter Financial Results and Provides Second Half Outlook Focusing Investments on Increasing U.S. and EU Galectin-3 Adoption 2013 Financial and Operational Guidance Provided Waltham, Mass., August 8, 2013 – BG Medicine, Inc. (NASDAQ: BGMD), a commercial stage company that is focused on the development and delivery of diagnostic solutions to aid |
|
| June 14, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 10, 2013 BG Medicine, Inc. |
|
| June 7, 2013 |
BG MEDICINE, INC. 4,106,071 shares of Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-188211 PROSPECTUS BG MEDICINE, INC. 4,106,071 shares of Common Stock This prospectus covers the sale of an aggregate of 4,106,071 shares of our common stock, $0.001 par value per share, or the Common Stock, by Aspire Capital Fund, LLC, referred to herein as Aspire Capital or the Selling Stockholder. The prices at which t |
|
| May 20, 2013 |
Form S-8 As filed with the Securities and Exchange Commission on May 20, 2013 Registration No. |
|
| May 20, 2013 |
Amendment No.1 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on May 20, 2013 Registration Statement No. 333-188211 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Pre-effective Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 BG MEDICINE, INC. (Exact Name of Registrant as Specified in Its Charter) Delaw |
|
| May 20, 2013 |
BG MEDICINE, INC. NON-QUALIFIED STOCK OPTION AGREEMENT EX-99.1 Exhibit 99.1 Execution Version BG MEDICINE, INC. NON-QUALIFIED STOCK OPTION AGREEMENT AGREEMENT made as of the 10th day of May 2013, by and between BG Medicine, Inc. (the “Company”), a Delaware corporation, and Paul Sohmer, M.D. (the “Participant”). WHEREAS, the Company desires to grant to the Participant an option to purchase shares of its common stock, $0.001 par value per share (the “Sh |
|
| May 17, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 14, 2013 BG Medicine, Inc. |
|
| May 10, 2013 |
BG Medicine Appoints Dr. Paul Sohmer as Chief Executive Officer EX-99.1 Exhibit 99.1 BG Medicine Appoints Dr. Paul Sohmer as Chief Executive Officer WALTHAM, Mass., May 9, 2013 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today announced that it has appointed Paul Sohmer, M.D., as its President & Chief Executive Officer and a member of its Board of Dire |
|
| May 10, 2013 |
BG Medicine, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) EX-99.2 Exhibit 99.2 BG Medicine, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) WALTHAM, Mass., May 10, 2013 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, announced today that the company granted a stock option to Paul Sohmer, M.D., the company’s newly appointed Presiden |
|
| May 10, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 8, 2013 BG Medicine, Inc. |
|
| May 9, 2013 |
EX-10.3 Exhibit 10.3 Execution Version AMENDMENT NO. 1 TO WARRANT This AMENDMENT NO. 1 TO WARRANT (this “Amendment”), is entered into and shall be effective as of May 8, 2013 (the “Effective Date”), by and between BG Medicine, Inc. (the “Issuer”) and Comerica Bank (“Holder”). Capitalized terms used but not defined herein shall have the meanings assigned to them in that certain Warrant by the Issue |
|
| May 9, 2013 |
EX-99.1 Exhibit 99.1 BG Medicine Reports 2013 First Quarter Financial Results Abbott and bioMérieux Obtain CE Mark and Launch Galectin-3 tests in EU BGM Galectin-3 Revenues Coupled with Operational Discipline Drive Improved Financial Results • Q1 BGM Galectin-3 test revenues grow 97% from Q1 2012 • Abbott obtains CE mark and launches ARCHITECT Galectin-3 assay in Europe • bioMérieux obtains CE mar |
|
| May 9, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 8, 2013 BG Medicine, Inc. |
|
| May 9, 2013 |
FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT EX-10.1 Exhibit 10.1 Execution Version FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of May 8, 2013, by and among BG MEDICINE, INC., a Delaware corporation (“Borrower”); GENERAL ELECTRIC CAPITAL CORPORATION, a Delaware corporation (in its individual capacity, “GE Capital”), for itself as Lender and as Agent |
|
| May 9, 2013 |
EX-10.2 Exhibit 10.2 Execution Version AMENDMENT NO. 1 TO WARRANT This AMENDMENT NO. 1 TO WARRANT (this “Amendment”), is entered into and shall be effective as of May 8, 2013 (the “Effective Date”), by and between BG Medicine, Inc. (the “Issuer”) and GE Capital Equity Investments, Inc. (“Holder”). Capitalized terms used but not defined herein shall have the meanings assigned to them in that certai |
|
| April 29, 2013 |
Registration Statement - FORM S-1 Form S-1 Table of Contents As filed with the Securities and Exchange Commission on April 29, 2013 Registration Statement No. |
|
| April 29, 2013 |
Form S-8 As filed with the Securities and Exchange Commission on April 29, 2013 Registration No. |
|
| April 23, 2013 |
Notice & Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 13, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 13, 2013 BG Medicine, Inc. |
|
| March 13, 2013 |
EX-99.1 Exhibit 99.1 BG Medicine Reports Fourth Quarter and Full Year 2012 Financial Results and Provides 2013 Outlook Fourth Quarter and Full Year BGM Galectin-3 Test Sales Grow Significantly • Q4 Revenues nearly triple from Q4 2011 • Product margins increase 10% from Q4 2011 • January 2013 $12.8 million public offering supplements Q4 2012 cash of $13.2 million • bioMérieux obtains CE mark for VI |
|
| February 26, 2013 |
BGMD / BG Medicine, Inc. / NEWCOGEN GROUP LLC - SCHEDULE 13D AMENDMENT NO. 1 Activist Investment Schedule 13D Amendment No. 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* BG Medicine, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 08861T107 (CUSIP Number) Charles Carelli Chief Financial Officer Flagship Ventures One Memorial Drive, 7th Floor Cambridge, MA 02142 |
|
| February 13, 2013 |
BGMD / BG Medicine, Inc. / GE ASSET MANAGEMENT - BG MEDICINE, INC. Passive Investment SC 13G/A 1 p13-0596sc13ga.htm BG MEDICINE, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.1)* BG Medicine, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 08861T107 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of This Statement) Check the app |
|
| February 11, 2013 |
BGMD / BG Medicine, Inc. / CLEARBRIDGE, LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* BG Medicine, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 08861T107 (CUSIP Number) January 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| January 30, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 30, 2013 BG Medicine, Inc. |
|
| January 30, 2013 |
BG Medicine, Inc. Announces Closing of Public Offering and Exercise of Over-Allotment Option Press Release Exhibit 99.1 BG Medicine, Inc. Announces Closing of Public Offering and Exercise of Over-Allotment Option WALTHAM, Mass., Jan. 30, 2013 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today announced the closing of its previously announced public offering of 6,000,000 shares of i |
|
| January 25, 2013 |
6,000,000 Shares of Common Stock Prospectus Supplement Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| January 25, 2013 |
Underwriting Agreement Exhibit 1.1 6,000,000 Shares of Common Stock par value $0.001 900,000 Over-Allotment Shares BG MEDICINE, INC. UNDERWRITING AGREEMENT January 25, 2013 LAZARD CAPITAL MARKETS LLC 30 Rockefeller Plaza New York, New York 10020 Dear Sirs: 1. INTRODUCTION. BG Medicine, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to Lazard Capital Markets LLC (the “Unde |
|
| January 25, 2013 |
Press Release Exhibit 99.1 BG Medicine, Inc. Prices $12.0 Million Public Offering of Common Stock Waltham, Mass., January 25, 2013 — BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today announced the sale of 6,000,000 shares of its common stock in an underwritten public offering at a price to the public of $2.0 |
|
| January 25, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 25, 2013 BG Medicine, Inc. |
|
| January 24, 2013 |
SUBJECT TO COMPLETION, DATED JANUARY 24, 2013 Preliminary Prospectus Supplement Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. |
|
| January 24, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 24, 2013 BG Medicine, Inc. |
|
| January 24, 2013 |
Business Overview Exhibit 99.3 BG Medicine, Inc. Overview We are a diagnostics company focused on the development and commercialization of novel cardiovascular diagnostic tests to address significant unmet medical needs, improve patient outcomes and contain healthcare costs. We are currently commercializing two diagnostic tests, the first of which is the BGM Galectin-3® test, which is available in |
|
| January 24, 2013 |
Registration Rights Agreement Exhibit 4.1 EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of January 24, 2013, by and between BG MEDICINE, INC., a Delaware corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and no |
|
| January 24, 2013 |
COMMON STOCK PURCHASE AGREEMENT Common Stock Purchase Agreement Exhibit 10.1 Execution Version COMMON STOCK PURCHASE AGREEMENT COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of January 24, 2013 by and between BG MEDICINE, INC., a Delaware corporation (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (the “Buyer”). Capitalized terms used herein and not otherwise defined herein are d |
|
| January 24, 2013 |
Risk Factors Exhibit 99.4 RISK FACTORS Investing in our common stock involves significant risks. We caution you that the risks and uncertainties we describe below, among others, could cause our actual results to differ materially from those expressed in forward-looking statements made by us or on our behalf in filings with the Securities and Exchange Commission, or SEC, press releases, communicati |
|
| January 24, 2013 |
BG Medicine, Inc. Announces Proposed Public Offering of Common Stock Press Release Exhibit 99.2 BG Medicine, Inc. Announces Proposed Public Offering of Common Stock WALTHAM, Mass., January 24, 2013 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. BG Medicin |
|
| January 24, 2013 |
Press Release Exhibit 99.1 BG Medicine, Inc. Enters into $12 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC WALTHAM, Mass., January 24, 2013 (GLOBE NEWSWIRE) – BG Medicine, Inc. (NASDAQ: BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, today announced that it has entered into a common stock purchase agreement with Aspire |
|
| January 7, 2013 |
Press Release Exhibit 99.1 January 2, 2013 BG Medicine Announces Obtaining CE Mark and Launching of Automated BGM Galectin-3 Test First Automated Test Launches in Europe and Territories Recognizing the CE Mark WALTHAM, Mass., Jan. 2, 2013 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced tod |
|
| January 7, 2013 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 2, 2013 BG Medicine, Inc. |
|
| January 2, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 27, 2012 BG Medicine, Inc. |
|
| December 14, 2012 |
Press Release Exhibit 99.1 December 11, 2012 BG Medicine Obtains CE Mark for CardioSCORE(TM) Test in Europe Innovative Blood Test for the Prediction of Major Cardiovascular Events Expected to Launch in the First Half of 2013 WALTHAM, Mass., Dec. 11, 2012 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascula |
|
| December 14, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 10, 2012 BG Medicine, Inc. |
|
| November 13, 2012 |
Commercial Strategy press release Exhibit 99.2 BG Medicine Outlines New Commercial Strategy Company to Assume Greater Control of Commercial Execution WALTHAM, Mass., November 13, 2012 — BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, today provided an update on its new commercial strategy to speed the adoption of its |
|
| November 13, 2012 |
BG Medicine Reports Third Quarter 2012 Financial Results and Provides Business Update Earnings press release Exhibit 99.1 BG Medicine Reports Third Quarter 2012 Financial Results and Provides Business Update Waltham, Mass., November 13, 2012 – BG Medicine, Inc. (NASDAQ: BGMD) today reported financial results for the third quarter ended September 30, 2012 and provided a business update. Total revenue increased to $0.6 million in the third quarter of 2012 compared to $0.2 million in |
|
| November 13, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 8, 2012 BG Medicine, Inc. |
|
| October 23, 2012 |
BG Medicine, Inc. Appoints Charles H. Abdalian, Jr. as Chief Financial Officer Press Release Exhibit 99.1 BG Medicine, Inc. Appoints Charles H. Abdalian, Jr. as Chief Financial Officer WALTHAM, Mass., Oct. 18, 2012 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that it has appointed Charles H. Abdalian, Jr., as the company’s Executive Vice President, Chief Fin |
|
| October 23, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 17, 2012 BG Medicine, Inc. |
|
| September 12, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 6, 2012 BG Medicine, Inc. |
|
| August 9, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 9, 2012 BG Medicine, Inc. |
|
| August 9, 2012 |
BG Medicine Announces Fiscal 2012 Second Quarter Results Press Release Exhibit 99.1 BG Medicine Announces Fiscal 2012 Second Quarter Results Waltham, Mass., August 9, 2012 – BG Medicine, Inc. (NASDAQ: BGMD) today announced its consolidated results of operations for the three and six months ended June 30, 2012 and provided a business update. The Company will host a conference call and webcast today, August 9, 2012, beginning at 8:30 a.m. Eastern Time (de |
|
| June 12, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 11, 2012 BG Medicine, Inc. |
|
| June 8, 2012 |
BG MEDICINE, INC. COMMON STOCK PREFERRED STOCK DEBT SECURITIES PURCHASE CONTRACTS Prospectus Table of Contents Filed Pursuant to Rule 424(b)(2) Registration Statement 333-181699 PROSPECTUS BG MEDICINE, INC. |
|
| May 25, 2012 |
Table of Contents As filed with the Securities and Exchange Commission on May 25, 2012 Registration No. |
|
| May 25, 2012 |
Exhibit 4.9 BG MEDICINE, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). 5 |
|
| May 25, 2012 |
Form S-8 As filed with the Securities and Exchange Commission on May 25, 2012 Registration No. |
|
| May 25, 2012 |
Form S-8 As filed with the Securities and Exchange Commission on May 25, 2012 Registration No. |
|
| May 25, 2012 |
Exhibit 4.8 BG MEDICINE, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE (1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c). 5.04(a) |
|
| May 15, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 15, 2012 BG Medicine, Inc. |
|
| May 15, 2012 |
Galectin-3 label expansion press release Exhibit 99.2 BG Medicine, Inc. Obtains CE Mark and Files 510(k) for Expanded BGM Galectin-3TM Indication - Expands Label to General Adult Population at Risk for Developing Heart Failure Based on Elevated Levels of Galectin-3 - Waltham, MA, May 15, 2012 — BG Medicine, Inc. (NASDAQ: BGMD), a company focused on the development and commercialization of novel ca |
|
| May 15, 2012 |
BG Medicine Announces Fiscal 2012 First Quarter Results Earnings press release Exhibit 99.1 BG Medicine Announces Fiscal 2012 First Quarter Results Waltham, Mass., May 15, 2012 – BG Medicine, Inc. (NASDAQ: BGMD) today announced its consolidated results of operations for the first quarter of fiscal year 2012 and provided a business update. The Company will host a conference call and webcast today, May 15, 2012, beginning at 8:00 a.m. Eastern Time (detai |
|
| April 30, 2012 |
Notice & Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 26, 2012 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 26, 2012 BG Medicine, Inc. |
|
| March 26, 2012 |
BG Medicine, Inc. Announces Important New Galectin-3 Findings Presented at American Press Release Exhibit 99.1 BG Medicine, Inc. Announces Important New Galectin-3 Findings Presented at American College of Cardiology’s (ACC) 61st Annual Scientific Session & Expo - Company to Discuss Results in Conference Call and Webcast Today at 8:45 a.m. ET - Waltham, MA, March 26, 2012 – BG Medicine, Inc. (NASDAQ: BGMD), a company focused on the development and commercialization of novel cardi |
|
| March 8, 2012 |
BG Medicine Announces Fourth Quarter and Full Year Fiscal 2011 Results Press Release Exhibit 99.1 BG Medicine Announces Fourth Quarter and Full Year Fiscal 2011 Results WALTHAM, MA, March 8, 2012 – BG Medicine, Inc. (NASDAQ: BGMD) today announced its consolidated results of operations for the fourth quarter and the full year ended December 31, 2011 and provided a business update. The Company will host a conference call and webcast today beginning at 8:30 am eastern t |
|
| March 8, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 8, 2012 BG Medicine, Inc. |
|
| February 16, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 10, 2012 BG Medicine, Inc. |
|
| February 16, 2012 |
BG Medicine, Inc. Appoints Brian S. Posner to Its Board of Directors Press Release announcing Appointment of Brian S. Posner Exhibit 99.2 February 13, 2012 BG Medicine, Inc. Appoints Brian S. Posner to Its Board of Directors WALTHAM, Mass., Feb. 13, 2012 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced the appointment of Brian S. Posner to its Board of Dir |
|
| February 16, 2012 |
BG Medicine, Inc. Secures $15 Million Loan Facility From GE Capital and Comerica Press Release announcing Loan Facility Exhibit 99.1 February 13, 2012 BG Medicine, Inc. Secures $15 Million Loan Facility From GE Capital and Comerica WALTHAM, Mass., Feb. 13, 2012 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that it has entered into a $15.0 million secured loan |
|
| February 16, 2012 |
EX-10.1 2 d302403dex101.htm LOAN AND SECURITY AGREEMENT Exhibit 10.1 Execution Version LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT, dated as of February 10, 2012 (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) is among GENERAL ELECTRIC CAPITAL CORPORATION (“GECC”), in its capacity as agent for Lenders (as defined below) (together with |
|
| February 16, 2012 |
Pledge Agreement Exhibit 10.4 Execution Version PLEDGE AGREEMENT This PLEDGE AGREEMENT, dated as of February 10, 2012 (together with all amendments, if any, from time to time hereto, this “Pledge Agreement”), by and among BG MEDICINE, INC., a Delaware corporation, (“Borrower”, and Borrower, together with any other Person that joins this Pledge Agreement as a Pledgor in accordance with Section 27, |
|
| February 16, 2012 |
- WARRANT ISSUED BY THE COMPANY TO COMERICA BANK Warrant issued by the Company to Comerica Bank Exhibit 10.6 WARRANT NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SUBJECT TO SECTION 6 BELOW, AND EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT, NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR A |
|
| February 16, 2012 |
- WARRANT ISSUED BY THE COMPANY TO GE CAPITAL EQUITY INVESTMENTS INC. Warrant issued by the Company to GE Capital Equity Investments Inc. Exhibit 10.5 WARRANT NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SUBJECT TO SECTION 6 BELOW, AND EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT, NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT |
|
| February 16, 2012 |
Promissory Note Exhibit 10.2 PROMISSORY NOTE February 10, 2012 FOR VALUE RECEIVED, BG MEDICINE, INC., a Delaware corporation located at the address stated below (“Borrower”), promises to pay to the order of GENERAL ELECTRIC CAPITAL CORPORATION or any subsequent holder hereof (each, a “Lender”), the principal sum of TEN MILLION and 00/100 Dollars ($10,000,000.00) or, if less, the aggregate unpaid p |
|
| February 16, 2012 |
Press Release announcing Positive Pivotal Validation Study Results Exhibit 99.3 February 13, 2012 BG Medicine Announces Positive Pivotal Validation Study Results for CardioSCORE, a New Diagnostic Blood Test to Identify Individuals at High Risk for Near-term Major Cardiovascular Events WALTHAM, Mass., Feb. 13, 2012 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the develop |
|
| February 16, 2012 |
Promissory Note Exhibit 10.3 PROMISSORY NOTE February 10, 2012 FOR VALUE RECEIVED, BG MEDICINE, INC., a Delaware corporation located at the address stated below (“Borrower”), promises to pay to the order of COMERICA BANK or any subsequent holder hereof (each, a “Lender”), the principal sum of FIVE MILLION and 00/100 Dollars ($5,000,000.00) or, if less, the aggregate unpaid principal amount of all |
|
| February 14, 2012 |
BGMD / BG Medicine, Inc. / CLEARBRIDGE, LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* BG Medicine, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 08861T107 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 14, 2012 |
BGMD / BG Medicine, Inc. / Gilde Agribusiness Management B.V. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 14, 2012 |
BGMD / BG Medicine, Inc. / CLEARBRIDGE, LLC - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* BG Medicine, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 08861T107 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)1 BG Medicine, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 08861T107 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filin |
|
| February 13, 2012 |
Investor Analyst Briefing Presentation Exhibit 99.1 February 13, 2012 BGMEDICINE Forward-Looking Statements This presentation contains forward-looking statements regarding future events or the future financial performance of the BG Medicine, Inc. These statements involve risks, uncertainties and assumptions and are based on the current estimates and assumptions of the BG Medicine management as of |
|
| February 13, 2012 |
Financial Statements and Exhibits - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 13, 2012 BG Medicine, Inc. |
|
| January 13, 2012 |
BG Medicine, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Press Release Dated January 13, 2012 Exhibit 99.2 BG Medicine, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) WALTHAM, Mass., January 13, 2012 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that the company granted a stock option to Eric Bouvier, the company’s |
|
| January 13, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 9, 2012 BG Medicine, Inc. |
|
| January 13, 2012 |
BG Medicine, Inc. Appoints Eric Bouvier as Chief Executive Officer Press Release Dated January 9, 2012 Exhibit 99.1 BG Medicine, Inc. Appoints Eric Bouvier as Chief Executive Officer WALTHAM, Mass., Jan. 9, 2012 (GLOBE NEWSWIRE) — BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that its Board of Directors has appointed Eric Bouvier, Ph.D., as the company’s new Presi |
